
    
      The objectives of this study are to evaluate the efficacy and safety of two sequential doses
      of 90Y-Ibritumomab Tiuxetan administered after salvage chemotherapy in patients with
      relapsed/refractory aggressive lymphoma non-eligible for HDC and ASCT.
    
  